返回 
加入收藏
西格列汀联合贝那普利治疗糖尿病肾病的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 西格列汀联合贝那普利治疗糖尿病肾病的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察西格列汀联合贝那普利治疗糖尿病肾病（DN）的临床效果。方法：将我院2014年9月－2015年6月收治的60例DN患者按随机数字表法分为西格列汀组、贝那普利组和联合用药组，各20例。在常规治疗基础上，西格列汀组患者口服西格列汀100 mg，qd；贝那普利组患者口服贝那普利10 mg，qd；联合用药组患者口服西格列汀100 mg+贝那普利10 mg，qd。患者血压若未达标，则将用药剂量加倍；疗程均为12周。测定3组患者治疗前后的24 h尿蛋白、白细胞介素6（IL-6）和血清胱抑素C（CysC）水平，观察临床疗效和不良反应发生情况。结果：联合用药组患者的总有效率（90.00％）显著高于西格列汀组（65.00％）和贝那普利组（70.00％），差异有统计学意义（P＜0.05）。治疗后，3组患者的24 h尿蛋白、IL-6和CysC水平均较治疗前显著降低，且联合用药组显著低于两单独用药组，差异均有统计学意义（P＜0.05）。西格列汀组和贝那普利组的上述指标比较，差异均无统计学意义（P＞0.05）。3组患者在治疗期间均未见明显不良反应发生。结论：西格列汀和贝那普利均能降低DN患者的24 h尿蛋白、IL-6和CysC水平，但联合用药的效果更显著，并具有更高的临床有效率，且不影响用药安全性。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy of sitagliptin combined with benazepril in the treatment of diabetic nephropathy （DN）. METHODS： Sixty DN patients admitted to our hospital during Sept. 2014-Jun. 2015 were divided into sitagliptin group， benazepril group， drug combination group according to random number table， with 20 cases in each group. Based on routine treatment， sitagliptin group was given sitagliptin 100 mg orally， qd； benazepril group was given Benazepril 10 mg orally， qd； drug combination group was given sitagliptin 100 mg+benazepril 10 mg orally， qd. The drug dosage would be doubled if the blood pressure of patients in 3 groups had not yet reached the standard. Treatment course of 3 groups lasted for 12 weeks. The levels of 24 h urine protein， IL-6 and Cys-C were measured in 3 groups before and after treatment. Clinical efficacies and the occurrence of ADR were observed. RESULTS： Total response rate of drug combination group （90.00％） was significantly higher than those of sitagliptin group （65.00％） and benazepril group （70.00％）； there was statistically significance （P＜0.05）. After treatment， the levels of 24 h urine protein， IL-6 and Cys-C in 3 groups were significantly lowered， compared to before treatment； those of drug combination group was significantly lower than those of other 2 groups； there was statistically significance （P＜0.05）. There was no statistical significance in above indexes between sitagliptin group and benazepril group （P＞0.05）. No obvious ADR was found in 3 groups during treatment. CONCLUSIONS： Both sitagliptin and benazepril can decrease the levels of 24 h urine protein， IL-6 and Cys-C， while drug combination shows better effect and clinical response rate， and does not influence the safety of drug use. |
| 期刊： | 2017年第28卷第5期 |
| 作者： | 吕爱玲，安民民，阮爱兵，盛昭，刘叶美，丁俊，吴雪 |
| AUTHORS： | LYU Ailing，AN Minmin，RUAN Aibing，SHENG Zhao，LIU Yemei，DING Jun，WU Xue |
| 关键字： | 西格列汀；贝那普利；联合用药；糖尿病肾病；24 h尿蛋白；白细胞介素6；血清胱抑素C |
| KEYWORDS： | Sitagliptin； Benazepril； Drug combination； Diabetic nephropathy； 24 h urine protein； IL-6； Cys-C |
| 阅读数： | 356 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
